Zosano Pharma Corp., a clinical-stage biopharmaceutical company focused on systemic administration of therapeutics using its Adhesive Dermally-Applied Microneedle (ADAM) technology, has released three registration batches of M207, the company’s lead development candidate. The registration batches will be used to support Zosano’s New Drug Application (NDA) filing with the U.S. FDA. Twelve months of room temperature stability for a product candidate are typically required in order for the FDA t...